Selected article for: "immunosuppressive therapy and infection risk"

Author: Azimzadeh, Maryam; Möhn, Nora; Ghane Ezabadi, Sajjad; Moghimi Esfandabadi, Zahra; Soleimani, Alireza; Ranjbar, Elaheh; Jahromi, Maliheh; Seyedebrahimi, Reihaneh; Skripuletz, Thomas; Moharrami Kasmaie, Farshad
Title: The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic
  • Cord-id: f1igsw7l
  • Document date: 2021_9_17
  • ID: f1igsw7l
    Snippet: A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. A
    Document: A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic.

    Search related documents:
    Co phrase search for related documents